Department of Health Economics, Weber, Madrid, Spain.
Department of Quantitative Methods in Economics and Management, University Las Palmas de Gran Canaria, Las Palmas, Spain.
Expert Rev Pharmacoecon Outcomes Res. 2022 Sep;22(6):941-953. doi: 10.1080/14737167.2022.2063842. Epub 2022 Apr 25.
Multi-criteria decision analysis (MCDA) was proposed to surmount arbitrary clinical decisions in the field of biological therapies for psoriatic patients. At the same time, MCDA may further highlight the potential of bimekizumab for the treatment of moderate-to-severe psoriasis, compared to placebo, adalimumab, ustekinumab, secukinumab, and even ixekizumab and risankizumab.
The EVIDEM framework was adapted to reflect relevant criteria for the assessment. Estimated values were obtained by means of an additive linear model combining weights and scores assigned by a multidisciplinary committee of 12 experts. Consistency and replicability were evaluated through an alternative weighting method and a re-test.
Bimekizumab was assessed by the committee as an intervention with a positive value contribution for the treatment of moderate-to-severe psoriasis in comparison to any of the alternatives. The drug provides a substantial therapeutical benefits and improves the health results reported by the patients, as it combines a higher level of clearance, rapidity, and persistence with a similar safety and tolerability profile.
Under a methodology with increasing use in the health field, bimekizumab was evaluated as a drug with a high added value for the treatment of moderate-to-severe psoriasis when compared to six different alternatives.
多准则决策分析（MCDA）被提出以克服生物治疗领域中针对银屑病患者的任意临床决策。同时，与安慰剂、阿达木单抗、乌司奴单抗、司库奇尤单抗相比，MCDA 可能进一步凸显了比美吉仑单抗治疗中重度银屑病的潜力，甚至与依奇珠单抗和 risankizumab 相比也是如此。
EVIDEM 框架进行了调整，以反映评估的相关标准。通过结合由 12 名多学科专家组成的委员会分配的权重和分数的加性线性模型来获得估计值。通过替代权重方法和重新测试评估一致性和可重复性。
委员会评估比美吉仑单抗作为一种干预措施，与任何其他替代药物相比，对中重度银屑病的治疗具有积极的价值贡献。该药物提供了实质性的治疗益处，并改善了患者报告的健康结果，因为它结合了更高水平的清除率、快速性和持久性，同时具有相似的安全性和耐受性。
在健康领域越来越多使用的方法学下，与六种不同的替代药物相比，比美吉仑单抗被评估为一种治疗中重度银屑病具有高附加值的药物。
